Product Information

GVOKE PFS 1-PK 1 MG/0.2 ML SYR is a brand product labeled by Xeris Pharmaceuticals, Inc., priced at $1600.2289 per ML under NDC 72065013111. Its NADAC has been published 327 times since May 20, 2020.

FDA first approved this application on Sep 10, 2019.

GVOKE PFS 1-PK 1 MG/0.2 ML SYR

glucagon injection, solution
$1600.2289per ML

Strength

1 mg/.2mL

NDC

72065013111

Classification

Brand

Dosage Form

INJECTION, SOLUTION

Route

SUBCUTANEOUS

Effective Date

8/19/2026

Active Ingredients

GLUCAGON

Approval Type

New Drug (NDA)

FDA Application

NDA212097

FDA Approved

9/10/2019

On Market Since

9/10/2019

Pharmacological Classes

Antihypoglycemic Agent
Decreased GI Motility
Decreased GI Smooth Muscle Tone
Decreased Glycolysis
Gastrointestinal Motility Inhibitor
Increased Gluconeogenesis
Increased Glycogenolysis

Price Statistics

The NADAC for GVOKE PFS 1-PK 1 MG/0.2 ML SYR has been published 327 times since May 20, 2020, and over the history we have for it it has risen 19.4%. The table below summarizes its recorded NADAC range and movement.

Current price$1600.2289 per ML
All-time high$1604.3171 (Jun 10, 2026)
All-time low$1340.0286 (May 20, 2020)
52-week high$1604.3171
52-week low$1557.3479
Median price$1468.9945
Average price$1464.1368
Largest weekly change+3.0% (Feb 15, 2023)
Weeks tracked327
Tracking sinceMay 20, 2020

Price History

1W

+0.1%

1M

+0.1%

3M

-0.3%

6M

-0.3%

1Y

+2.7%

3Y

+8.9%

5Y

+19.0%

All

+19.4%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of GVOKE PFS 1-PK 1 MG/0.2 ML SYR?

The current National Average Drug Acquisition Cost (NADAC) for GVOKE PFS 1-PK 1 MG/0.2 ML SYR, manufactured by Xeris Pharmaceuticals, Inc., is $1600.2289 per ML (NDC 72065013111), effective Aug 19, 2026.

How has the price of GVOKE PFS 1-PK 1 MG/0.2 ML SYR changed over time?

Over the history we have for it, the NADAC for GVOKE PFS 1-PK 1 MG/0.2 ML SYR has risen 19.4%. It has been tracked across 327 weekly CMS publications since May 20, 2020.

What are the highest and lowest recorded NADAC prices for GVOKE PFS 1-PK 1 MG/0.2 ML SYR?

Since May 20, 2020, the NADAC for GVOKE PFS 1-PK 1 MG/0.2 ML SYR has ranged from a low of $1340.0286 (May 20, 2020) to a high of $1604.3171 (Jun 10, 2026), with a median of $1468.9945 per ML.

Are there cheaper alternatives to GVOKE PFS 1-PK 1 MG/0.2 ML SYR?

1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as GVOKE PFS 1-PK 1 MG/0.2 ML SYR in a comparable dosage form, but none are currently priced below it.

Who manufactures GVOKE PFS 1-PK 1 MG/0.2 ML SYR?

GVOKE PFS 1-PK 1 MG/0.2 ML SYR (NDC 72065013111) is labeled by Xeris Pharmaceuticals, Inc., and CMS classifies it as a brand product.